nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—SLC22A6—Captopril—systemic scleroderma	0.142	0.328	CbGbCtD
Methazolamide—CA5B—cervicothoracic ganglion—systemic scleroderma	0.0909	0.507	CbGeAlD
Methazolamide—CYP2C9—Leflunomide—systemic scleroderma	0.0831	0.192	CbGbCtD
Methazolamide—CYP2D6—Captopril—systemic scleroderma	0.0597	0.138	CbGbCtD
Methazolamide—CYP2C19—Prednisone—systemic scleroderma	0.0494	0.114	CbGbCtD
Methazolamide—SLC22A6—Methotrexate—systemic scleroderma	0.0449	0.104	CbGbCtD
Methazolamide—CYP2C9—cardial valve—systemic scleroderma	0.0299	0.167	CbGeAlD
Methazolamide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0299	0.069	CbGbCtD
Methazolamide—CYP3A4—Prednisone—systemic scleroderma	0.0239	0.0551	CbGbCtD
Methazolamide—CA7—digestive system—systemic scleroderma	0.00459	0.0256	CbGeAlD
Methazolamide—CA12—connective tissue—systemic scleroderma	0.00413	0.023	CbGeAlD
Methazolamide—CA9—digestive system—systemic scleroderma	0.00403	0.0225	CbGeAlD
Methazolamide—CA9—tendon—systemic scleroderma	0.00384	0.0214	CbGeAlD
Methazolamide—CA14—tendon—systemic scleroderma	0.00364	0.0203	CbGeAlD
Methazolamide—CA12—digestive system—systemic scleroderma	0.00298	0.0166	CbGeAlD
Methazolamide—CA5B—tendon—systemic scleroderma	0.00255	0.0142	CbGeAlD
Methazolamide—CA12—lung—systemic scleroderma	0.00249	0.0139	CbGeAlD
Methazolamide—CA1—digestive system—systemic scleroderma	0.00236	0.0132	CbGeAlD
Methazolamide—CA5B—lung—systemic scleroderma	0.00223	0.0125	CbGeAlD
Methazolamide—CA2—connective tissue—systemic scleroderma	0.00212	0.0118	CbGeAlD
Methazolamide—CA1—lung—systemic scleroderma	0.00197	0.011	CbGeAlD
Methazolamide—CA2—smooth muscle tissue—systemic scleroderma	0.00194	0.0108	CbGeAlD
Methazolamide—CA2—skin of body—systemic scleroderma	0.00191	0.0107	CbGeAlD
Methazolamide—CA4—digestive system—systemic scleroderma	0.00185	0.0103	CbGeAlD
Methazolamide—Convulsion—Pentoxifylline—systemic scleroderma	0.00183	0.00472	CcSEcCtD
Methazolamide—Haemolytic anaemia—Mycophenolate mofetil—systemic scleroderma	0.00183	0.00471	CcSEcCtD
Methazolamide—Pancytopenia—Leflunomide—systemic scleroderma	0.0018	0.00464	CcSEcCtD
Methazolamide—Discomfort—Pentoxifylline—systemic scleroderma	0.00178	0.00458	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Azathioprine—systemic scleroderma	0.00177	0.00457	CcSEcCtD
Methazolamide—CA4—tendon—systemic scleroderma	0.00176	0.0098	CbGeAlD
Methazolamide—Erythema multiforme—Captopril—systemic scleroderma	0.00174	0.00448	CcSEcCtD
Methazolamide—Confusional state—Pentoxifylline—systemic scleroderma	0.00174	0.00448	CcSEcCtD
Methazolamide—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00172	0.00444	CcSEcCtD
Methazolamide—Pancytopenia—Mycophenolic acid—systemic scleroderma	0.00171	0.00442	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Lisinopril—systemic scleroderma	0.00169	0.00437	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Leflunomide—systemic scleroderma	0.00167	0.00432	CcSEcCtD
Methazolamide—CYP2C19—digestive system—systemic scleroderma	0.00167	0.00931	CbGeAlD
Methazolamide—Agranulocytosis—Azathioprine—systemic scleroderma	0.00167	0.0043	CcSEcCtD
Methazolamide—Anorexia—Pentoxifylline—systemic scleroderma	0.00164	0.00424	CcSEcCtD
Methazolamide—Haematuria—Leflunomide—systemic scleroderma	0.00161	0.00415	CcSEcCtD
Methazolamide—Agranulocytosis—Leflunomide—systemic scleroderma	0.00157	0.00406	CcSEcCtD
Methazolamide—Dysgeusia—Captopril—systemic scleroderma	0.00157	0.00404	CcSEcCtD
Methazolamide—Pancytopenia—Lisinopril—systemic scleroderma	0.00154	0.00398	CcSEcCtD
Methazolamide—CA4—lung—systemic scleroderma	0.00154	0.0086	CbGeAlD
Methazolamide—Haematuria—Mycophenolic acid—systemic scleroderma	0.00153	0.00396	CcSEcCtD
Methazolamide—Somnolence—Pentoxifylline—systemic scleroderma	0.00153	0.00395	CcSEcCtD
Methazolamide—CA2—digestive system—systemic scleroderma	0.00153	0.00853	CbGeAlD
Methazolamide—Dyspepsia—Pentoxifylline—systemic scleroderma	0.00152	0.00391	CcSEcCtD
Methazolamide—Erythema multiforme—Azathioprine—systemic scleroderma	0.00152	0.00391	CcSEcCtD
Methazolamide—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.0015	0.00388	CcSEcCtD
Methazolamide—Decreased appetite—Pentoxifylline—systemic scleroderma	0.0015	0.00386	CcSEcCtD
Methazolamide—Anaphylactic shock—Mometasone—systemic scleroderma	0.00149	0.00384	CcSEcCtD
Methazolamide—Ill-defined disorder—Captopril—systemic scleroderma	0.00148	0.00383	CcSEcCtD
Methazolamide—Photosensitivity reaction—Lisinopril—systemic scleroderma	0.00148	0.00383	CcSEcCtD
Methazolamide—CA2—tendon—systemic scleroderma	0.00146	0.00812	CbGeAlD
Methazolamide—Malaise—Captopril—systemic scleroderma	0.00144	0.00372	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.00144	0.00371	CcSEcCtD
Methazolamide—Erythema multiforme—Leflunomide—systemic scleroderma	0.00143	0.00369	CcSEcCtD
Methazolamide—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.00142	0.00366	CcSEcCtD
Methazolamide—Anorexia—Mometasone—systemic scleroderma	0.00142	0.00366	CcSEcCtD
Methazolamide—Haematuria—Lisinopril—systemic scleroderma	0.00138	0.00357	CcSEcCtD
Methazolamide—Urticaria—Pentoxifylline—systemic scleroderma	0.00137	0.00353	CcSEcCtD
Methazolamide—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00136	0.00351	CcSEcCtD
Methazolamide—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00349	CcSEcCtD
Methazolamide—Agranulocytosis—Lisinopril—systemic scleroderma	0.00135	0.00349	CcSEcCtD
Methazolamide—Tinnitus—Mycophenolic acid—systemic scleroderma	0.00135	0.00348	CcSEcCtD
Methazolamide—Discomfort—Captopril—systemic scleroderma	0.00135	0.00347	CcSEcCtD
Methazolamide—Paraesthesia—Mometasone—systemic scleroderma	0.00133	0.00344	CcSEcCtD
Methazolamide—Confusional state—Captopril—systemic scleroderma	0.00132	0.0034	CcSEcCtD
Methazolamide—Dyspepsia—Mometasone—systemic scleroderma	0.00131	0.00338	CcSEcCtD
Methazolamide—Anaphylactic shock—Captopril—systemic scleroderma	0.00131	0.00337	CcSEcCtD
Methazolamide—CYP2C9—digestive system—systemic scleroderma	0.0013	0.00722	CbGeAlD
Methazolamide—Ill-defined disorder—Azathioprine—systemic scleroderma	0.0013	0.00334	CcSEcCtD
Methazolamide—Decreased appetite—Mometasone—systemic scleroderma	0.00129	0.00333	CcSEcCtD
Methazolamide—Dysgeusia—Leflunomide—systemic scleroderma	0.00129	0.00333	CcSEcCtD
Methazolamide—Fatigue—Mometasone—systemic scleroderma	0.00128	0.00331	CcSEcCtD
Methazolamide—CA2—lung—systemic scleroderma	0.00128	0.00713	CbGeAlD
Methazolamide—Malaise—Azathioprine—systemic scleroderma	0.00126	0.00325	CcSEcCtD
Methazolamide—Melaena—Methotrexate—systemic scleroderma	0.00126	0.00324	CcSEcCtD
Methazolamide—Leukopenia—Azathioprine—systemic scleroderma	0.00125	0.00322	CcSEcCtD
Methazolamide—Anorexia—Captopril—systemic scleroderma	0.00124	0.00321	CcSEcCtD
Methazolamide—Asthenia—Pentoxifylline—systemic scleroderma	0.00124	0.00319	CcSEcCtD
Methazolamide—Erythema multiforme—Lisinopril—systemic scleroderma	0.00123	0.00317	CcSEcCtD
Methazolamide—CYP2E1—digestive system—systemic scleroderma	0.00123	0.00684	CbGeAlD
Methazolamide—Ill-defined disorder—Leflunomide—systemic scleroderma	0.00122	0.00316	CcSEcCtD
Methazolamide—Tinnitus—Lisinopril—systemic scleroderma	0.00121	0.00313	CcSEcCtD
Methazolamide—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00312	CcSEcCtD
Methazolamide—Aplastic anaemia—Methotrexate—systemic scleroderma	0.00121	0.00312	CcSEcCtD
Methazolamide—Malaise—Leflunomide—systemic scleroderma	0.00119	0.00307	CcSEcCtD
Methazolamide—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00306	CcSEcCtD
Methazolamide—Vertigo—Leflunomide—systemic scleroderma	0.00118	0.00306	CcSEcCtD
Methazolamide—Leukopenia—Leflunomide—systemic scleroderma	0.00118	0.00305	CcSEcCtD
Methazolamide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00118	0.00304	CcSEcCtD
Methazolamide—Body temperature increased—Mometasone—systemic scleroderma	0.00118	0.00303	CcSEcCtD
Methazolamide—Discomfort—Azathioprine—systemic scleroderma	0.00117	0.00303	CcSEcCtD
Methazolamide—Paraesthesia—Captopril—systemic scleroderma	0.00117	0.00302	CcSEcCtD
Methazolamide—CYP2E1—tendon—systemic scleroderma	0.00117	0.00651	CbGeAlD
Methazolamide—Ill-defined disorder—Mycophenolic acid—systemic scleroderma	0.00117	0.00301	CcSEcCtD
Methazolamide—Urine output increased—Methotrexate—systemic scleroderma	0.00116	0.003	CcSEcCtD
Methazolamide—Somnolence—Captopril—systemic scleroderma	0.00116	0.00299	CcSEcCtD
Methazolamide—Dyspepsia—Captopril—systemic scleroderma	0.00115	0.00297	CcSEcCtD
Methazolamide—Decreased appetite—Captopril—systemic scleroderma	0.00113	0.00293	CcSEcCtD
Methazolamide—Malaise—Mycophenolic acid—systemic scleroderma	0.00113	0.00293	CcSEcCtD
Methazolamide—Vertigo—Mycophenolic acid—systemic scleroderma	0.00113	0.00292	CcSEcCtD
Methazolamide—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00113	0.0029	CcSEcCtD
Methazolamide—Fatigue—Captopril—systemic scleroderma	0.00113	0.0029	CcSEcCtD
Methazolamide—Dysgeusia—Lisinopril—systemic scleroderma	0.00111	0.00286	CcSEcCtD
Methazolamide—Discomfort—Leflunomide—systemic scleroderma	0.00111	0.00286	CcSEcCtD
Methazolamide—Vomiting—Pentoxifylline—systemic scleroderma	0.0011	0.00283	CcSEcCtD
Methazolamide—Convulsion—Mycophenolic acid—systemic scleroderma	0.00109	0.00281	CcSEcCtD
Methazolamide—Rash—Pentoxifylline—systemic scleroderma	0.00109	0.0028	CcSEcCtD
Methazolamide—Dermatitis—Pentoxifylline—systemic scleroderma	0.00109	0.0028	CcSEcCtD
Methazolamide—Headache—Pentoxifylline—systemic scleroderma	0.00108	0.00278	CcSEcCtD
Methazolamide—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00108	0.00278	CcSEcCtD
Methazolamide—Feeling abnormal—Captopril—systemic scleroderma	0.00108	0.00278	CcSEcCtD
Methazolamide—Asthenia—Mometasone—systemic scleroderma	0.00107	0.00275	CcSEcCtD
Methazolamide—Photosensitivity—Methotrexate—systemic scleroderma	0.00106	0.00274	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—systemic scleroderma	0.00106	0.00274	CcSEcCtD
Methazolamide—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00274	CcSEcCtD
Methazolamide—Discomfort—Mycophenolic acid—systemic scleroderma	0.00106	0.00273	CcSEcCtD
Methazolamide—Ill-defined disorder—Lisinopril—systemic scleroderma	0.00105	0.00271	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—systemic scleroderma	0.00104	0.00268	CcSEcCtD
Methazolamide—Confusional state—Mycophenolic acid—systemic scleroderma	0.00104	0.00267	CcSEcCtD
Methazolamide—Body temperature increased—Captopril—systemic scleroderma	0.00103	0.00266	CcSEcCtD
Methazolamide—Anorexia—Leflunomide—systemic scleroderma	0.00103	0.00265	CcSEcCtD
Methazolamide—CYP2E1—lung—systemic scleroderma	0.00103	0.00572	CbGeAlD
Methazolamide—Nausea—Pentoxifylline—systemic scleroderma	0.00102	0.00264	CcSEcCtD
Methazolamide—Malaise—Lisinopril—systemic scleroderma	0.00102	0.00264	CcSEcCtD
Methazolamide—Vertigo—Lisinopril—systemic scleroderma	0.00102	0.00263	CcSEcCtD
Methazolamide—Diarrhoea—Mometasone—systemic scleroderma	0.00102	0.00262	CcSEcCtD
Methazolamide—Leukopenia—Lisinopril—systemic scleroderma	0.00101	0.00262	CcSEcCtD
Methazolamide—CYP3A4—digestive system—systemic scleroderma	0.000988	0.00551	CbGeAlD
Methazolamide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000984	0.00254	CcSEcCtD
Methazolamide—Anorexia—Mycophenolic acid—systemic scleroderma	0.000978	0.00252	CcSEcCtD
Methazolamide—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000972	0.00251	CcSEcCtD
Methazolamide—CYP2D6—digestive system—systemic scleroderma	0.000972	0.00542	CbGeAlD
Methazolamide—Paraesthesia—Leflunomide—systemic scleroderma	0.000966	0.00249	CcSEcCtD
Methazolamide—Discomfort—Lisinopril—systemic scleroderma	0.000953	0.00246	CcSEcCtD
Methazolamide—Dyspepsia—Leflunomide—systemic scleroderma	0.000947	0.00244	CcSEcCtD
Methazolamide—Vomiting—Mometasone—systemic scleroderma	0.000945	0.00244	CcSEcCtD
Methazolamide—Feeling abnormal—Azathioprine—systemic scleroderma	0.000939	0.00242	CcSEcCtD
Methazolamide—Rash—Mometasone—systemic scleroderma	0.000937	0.00242	CcSEcCtD
Methazolamide—Asthenia—Captopril—systemic scleroderma	0.000937	0.00242	CcSEcCtD
Methazolamide—Dermatitis—Mometasone—systemic scleroderma	0.000936	0.00242	CcSEcCtD
Methazolamide—Decreased appetite—Leflunomide—systemic scleroderma	0.000935	0.00241	CcSEcCtD
Methazolamide—Confusional state—Lisinopril—systemic scleroderma	0.000932	0.00241	CcSEcCtD
Methazolamide—Headache—Mometasone—systemic scleroderma	0.000931	0.0024	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000929	0.0024	CcSEcCtD
Methazolamide—Fatigue—Leflunomide—systemic scleroderma	0.000928	0.00239	CcSEcCtD
Methazolamide—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000925	0.00239	CcSEcCtD
Methazolamide—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000922	0.00238	CcSEcCtD
Methazolamide—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000921	0.00238	CcSEcCtD
Methazolamide—Somnolence—Mycophenolic acid—systemic scleroderma	0.000913	0.00235	CcSEcCtD
Methazolamide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000904	0.00233	CcSEcCtD
Methazolamide—Body temperature increased—Azathioprine—systemic scleroderma	0.000901	0.00232	CcSEcCtD
Methazolamide—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000895	0.00231	CcSEcCtD
Methazolamide—Diarrhoea—Captopril—systemic scleroderma	0.000893	0.0023	CcSEcCtD
Methazolamide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000892	0.0023	CcSEcCtD
Methazolamide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000892	0.0023	CcSEcCtD
Methazolamide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000888	0.00229	CcSEcCtD
Methazolamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000887	0.00229	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000886	0.00229	CcSEcCtD
Methazolamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000885	0.00228	CcSEcCtD
Methazolamide—Nausea—Mometasone—systemic scleroderma	0.000883	0.00228	CcSEcCtD
Methazolamide—Anorexia—Lisinopril—systemic scleroderma	0.000881	0.00227	CcSEcCtD
Methazolamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00086	0.00222	CcSEcCtD
Methazolamide—Urticaria—Leflunomide—systemic scleroderma	0.000855	0.00221	CcSEcCtD
Methazolamide—Body temperature increased—Leflunomide—systemic scleroderma	0.000851	0.00219	CcSEcCtD
Methazolamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000846	0.00218	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000841	0.00217	CcSEcCtD
Methazolamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000835	0.00215	CcSEcCtD
Methazolamide—Paraesthesia—Lisinopril—systemic scleroderma	0.00083	0.00214	CcSEcCtD
Methazolamide—Vomiting—Captopril—systemic scleroderma	0.00083	0.00214	CcSEcCtD
Methazolamide—Rash—Captopril—systemic scleroderma	0.000823	0.00212	CcSEcCtD
Methazolamide—Dermatitis—Captopril—systemic scleroderma	0.000822	0.00212	CcSEcCtD
Methazolamide—Somnolence—Lisinopril—systemic scleroderma	0.000822	0.00212	CcSEcCtD
Methazolamide—Headache—Captopril—systemic scleroderma	0.000818	0.00211	CcSEcCtD
Methazolamide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000817	0.00211	CcSEcCtD
Methazolamide—Dyspepsia—Lisinopril—systemic scleroderma	0.000814	0.0021	CcSEcCtD
Methazolamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000811	0.00209	CcSEcCtD
Methazolamide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00081	0.00209	CcSEcCtD
Methazolamide—Decreased appetite—Lisinopril—systemic scleroderma	0.000804	0.00207	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000798	0.00206	CcSEcCtD
Methazolamide—Fatigue—Lisinopril—systemic scleroderma	0.000797	0.00206	CcSEcCtD
Methazolamide—Diarrhoea—Azathioprine—systemic scleroderma	0.00078	0.00201	CcSEcCtD
Methazolamide—Nausea—Captopril—systemic scleroderma	0.000775	0.002	CcSEcCtD
Methazolamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000772	0.00199	CcSEcCtD
Methazolamide—Asthenia—Leflunomide—systemic scleroderma	0.000772	0.00199	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—systemic scleroderma	0.000766	0.00198	CcSEcCtD
Methazolamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000762	0.00197	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000737	0.0019	CcSEcCtD
Methazolamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000736	0.0019	CcSEcCtD
Methazolamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000736	0.0019	CcSEcCtD
Methazolamide—Urticaria—Lisinopril—systemic scleroderma	0.000735	0.0019	CcSEcCtD
Methazolamide—Body temperature increased—Lisinopril—systemic scleroderma	0.000731	0.00189	CcSEcCtD
Methazolamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000727	0.00188	CcSEcCtD
Methazolamide—Vomiting—Azathioprine—systemic scleroderma	0.000724	0.00187	CcSEcCtD
Methazolamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00072	0.00186	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—systemic scleroderma	0.00072	0.00186	CcSEcCtD
Methazolamide—Rash—Azathioprine—systemic scleroderma	0.000718	0.00185	CcSEcCtD
Methazolamide—Dermatitis—Azathioprine—systemic scleroderma	0.000718	0.00185	CcSEcCtD
Methazolamide—Headache—Azathioprine—systemic scleroderma	0.000714	0.00184	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000713	0.00184	CcSEcCtD
Methazolamide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000713	0.00184	CcSEcCtD
Methazolamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000704	0.00182	CcSEcCtD
Methazolamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000702	0.00181	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000699	0.0018	CcSEcCtD
Methazolamide—Haematuria—Methotrexate—systemic scleroderma	0.000686	0.00177	CcSEcCtD
Methazolamide—Vomiting—Leflunomide—systemic scleroderma	0.000684	0.00177	CcSEcCtD
Methazolamide—Rash—Leflunomide—systemic scleroderma	0.000678	0.00175	CcSEcCtD
Methazolamide—Dermatitis—Leflunomide—systemic scleroderma	0.000678	0.00175	CcSEcCtD
Methazolamide—Nausea—Azathioprine—systemic scleroderma	0.000677	0.00175	CcSEcCtD
Methazolamide—Headache—Leflunomide—systemic scleroderma	0.000674	0.00174	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000671	0.00173	CcSEcCtD
Methazolamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000668	0.00172	CcSEcCtD
Methazolamide—Asthenia—Lisinopril—systemic scleroderma	0.000663	0.00171	CcSEcCtD
Methazolamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000653	0.00168	CcSEcCtD
Methazolamide—Rash—Mycophenolic acid—systemic scleroderma	0.000647	0.00167	CcSEcCtD
Methazolamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000647	0.00167	CcSEcCtD
Methazolamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000644	0.00166	CcSEcCtD
Methazolamide—Headache—Mycophenolic acid—systemic scleroderma	0.000643	0.00166	CcSEcCtD
Methazolamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00064	0.00165	CcSEcCtD
Methazolamide—Nausea—Leflunomide—systemic scleroderma	0.000639	0.00165	CcSEcCtD
Methazolamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000633	0.00163	CcSEcCtD
Methazolamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000624	0.00161	CcSEcCtD
Methazolamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000611	0.00158	CcSEcCtD
Methazolamide—Nausea—Mycophenolic acid—systemic scleroderma	0.00061	0.00157	CcSEcCtD
Methazolamide—Malaise—Prednisone—systemic scleroderma	0.000607	0.00157	CcSEcCtD
Methazolamide—Vertigo—Prednisone—systemic scleroderma	0.000604	0.00156	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—systemic scleroderma	0.000602	0.00155	CcSEcCtD
Methazolamide—Vomiting—Lisinopril—systemic scleroderma	0.000588	0.00152	CcSEcCtD
Methazolamide—Rash—Lisinopril—systemic scleroderma	0.000583	0.0015	CcSEcCtD
Methazolamide—Convulsion—Prednisone—systemic scleroderma	0.000583	0.0015	CcSEcCtD
Methazolamide—Dermatitis—Lisinopril—systemic scleroderma	0.000582	0.0015	CcSEcCtD
Methazolamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000581	0.0015	CcSEcCtD
Methazolamide—Headache—Lisinopril—systemic scleroderma	0.000579	0.00149	CcSEcCtD
Methazolamide—Discomfort—Prednisone—systemic scleroderma	0.000566	0.00146	CcSEcCtD
Methazolamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000554	0.00143	CcSEcCtD
Methazolamide—Dysgeusia—Methotrexate—systemic scleroderma	0.000551	0.00142	CcSEcCtD
Methazolamide—Nausea—Lisinopril—systemic scleroderma	0.000549	0.00142	CcSEcCtD
Methazolamide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000549	0.00142	CcSEcCtD
Methazolamide—Anorexia—Prednisone—systemic scleroderma	0.000523	0.00135	CcSEcCtD
Methazolamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000522	0.00135	CcSEcCtD
Methazolamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000515	0.00133	CcSEcCtD
Methazolamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000511	0.00132	CcSEcCtD
Methazolamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00051	0.00132	CcSEcCtD
Methazolamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000507	0.00131	CcSEcCtD
Methazolamide—Malaise—Methotrexate—systemic scleroderma	0.000507	0.00131	CcSEcCtD
Methazolamide—Vertigo—Methotrexate—systemic scleroderma	0.000505	0.0013	CcSEcCtD
Methazolamide—Leukopenia—Methotrexate—systemic scleroderma	0.000503	0.0013	CcSEcCtD
Methazolamide—Paraesthesia—Prednisone—systemic scleroderma	0.000493	0.00127	CcSEcCtD
Methazolamide—Convulsion—Methotrexate—systemic scleroderma	0.000487	0.00126	CcSEcCtD
Methazolamide—Dyspepsia—Prednisone—systemic scleroderma	0.000483	0.00125	CcSEcCtD
Methazolamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000481	0.00124	CcSEcCtD
Methazolamide—Decreased appetite—Prednisone—systemic scleroderma	0.000477	0.00123	CcSEcCtD
Methazolamide—Fatigue—Prednisone—systemic scleroderma	0.000473	0.00122	CcSEcCtD
Methazolamide—Discomfort—Methotrexate—systemic scleroderma	0.000473	0.00122	CcSEcCtD
Methazolamide—Confusional state—Methotrexate—systemic scleroderma	0.000463	0.00119	CcSEcCtD
Methazolamide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000459	0.00118	CcSEcCtD
Methazolamide—Feeling abnormal—Prednisone—systemic scleroderma	0.000453	0.00117	CcSEcCtD
Methazolamide—Anorexia—Methotrexate—systemic scleroderma	0.000437	0.00113	CcSEcCtD
Methazolamide—Urticaria—Prednisone—systemic scleroderma	0.000436	0.00113	CcSEcCtD
Methazolamide—Body temperature increased—Prednisone—systemic scleroderma	0.000434	0.00112	CcSEcCtD
Methazolamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000412	0.00106	CcSEcCtD
Methazolamide—Somnolence—Methotrexate—systemic scleroderma	0.000408	0.00105	CcSEcCtD
Methazolamide—Dyspepsia—Methotrexate—systemic scleroderma	0.000404	0.00104	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—systemic scleroderma	0.000399	0.00103	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000396	0.00102	CcSEcCtD
Methazolamide—Fatigue—Methotrexate—systemic scleroderma	0.000396	0.00102	CcSEcCtD
Methazolamide—Asthenia—Prednisone—systemic scleroderma	0.000394	0.00102	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000378	0.000976	CcSEcCtD
Methazolamide—Diarrhoea—Prednisone—systemic scleroderma	0.000376	0.000969	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—systemic scleroderma	0.000365	0.000941	CcSEcCtD
Methazolamide—Body temperature increased—Methotrexate—systemic scleroderma	0.000363	0.000936	CcSEcCtD
Methazolamide—Vomiting—Prednisone—systemic scleroderma	0.000349	0.000901	CcSEcCtD
Methazolamide—Rash—Prednisone—systemic scleroderma	0.000346	0.000893	CcSEcCtD
Methazolamide—Dermatitis—Prednisone—systemic scleroderma	0.000346	0.000893	CcSEcCtD
Methazolamide—Headache—Prednisone—systemic scleroderma	0.000344	0.000888	CcSEcCtD
Methazolamide—Asthenia—Methotrexate—systemic scleroderma	0.000329	0.00085	CcSEcCtD
Methazolamide—Nausea—Prednisone—systemic scleroderma	0.000326	0.000842	CcSEcCtD
Methazolamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000314	0.00081	CcSEcCtD
Methazolamide—Vomiting—Methotrexate—systemic scleroderma	0.000292	0.000753	CcSEcCtD
Methazolamide—Rash—Methotrexate—systemic scleroderma	0.000289	0.000747	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—systemic scleroderma	0.000289	0.000746	CcSEcCtD
Methazolamide—Headache—Methotrexate—systemic scleroderma	0.000287	0.000742	CcSEcCtD
Methazolamide—Nausea—Methotrexate—systemic scleroderma	0.000273	0.000703	CcSEcCtD
